Liraglutide in patients with non-alcoholic steatohepatitis

February 16, 2016 Glucagon-like peptide 1 (GLP-1) analogues are licensed for type 2 diabetes, but they could also be effective in treating patients with non-alcoholic steatohepatitis. To test this, researchers injected the long-acting GLP-1 analogue liraglutide into...

Critics see accountability risk if FDA rule changes take hold

February 16, 2016 Under revised language proposed by FDA, companies no longer have to “provide adequate labeling” for non-FDA-approved uses of their products that they know about. Patient advocates worry that companies will use the new rule to avoid liability for...

US reaches $8 million settlement with CVS Pharmacy

February 16, 2016 CVS Pharmacy has agreed to pay $8 million to the United States to resolve claims that its pharmacies in Maryland violated the Controlled Substances Act (CSA) by dispensing controlled substances pursuant to prescriptions that were not issued for a...

Diabetes as a compelling indication for use of RAS blockers

February 16, 2016 People with type 2 diabetes are susceptible to cardiovascular and renal events, but health groups are divided about which antihypertensive agent offers optimal protection against associated outcomes. Some—including the American Diabetes Association...